X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This new agreement is based on the initial multi-year research collaboration between MSK and OSE Immunotherapeutics to explore the preclinical potential against IL-7R Acute Lymphoblastic Leukemia.
Lead Product(s): CAR-T Based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Memorial Sloan Kettering Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2024
Details:
FR104 is a pegylated monoclonal antibody fragment that bind to and blocks CD28-mediated effector-T cell co-stimulation, that acts as a natural brake on the body’s immune responses for transplantation.
Lead Product(s): FR104
Therapeutic Area: Immunology Product Name: VEL-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nantes University Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Details:
The collaboration aims to support the advancement of company's investigational product BI 765063, an anti-SIRPα immuno-oncology compound for the treatment of neoplasms.
Lead Product(s): BI 765063,BI 754091
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2024
Details:
Under the licensing agreement, AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
Lead Product(s): OSE-230
Therapeutic Area: Immunology Product Name: OSE-230
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $713.0 million Upfront Cash: $48.0 million
Deal Type: Licensing Agreement April 16, 2024
Details:
The funding aims to support the company to focus on the clinical development of Tedop (OSE2101) neoepitope-based cancer vaccine. It is being evaluated in the clinical trial for the treatment of HLA-A2 positive non-small cell lung cancer.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 10, 2024
Details:
The partnership aims to focus on the development of OSE-230, which is an agonist antibody against ChemR23. It is being evaluated in the preclinical trial studies for the treatment of chronic and severe inflammation.
Lead Product(s): OSE-230
Therapeutic Area: Immunology Product Name: OSE-230
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $713.0 million Upfront Cash: $48.0 million
Deal Type: Partnership February 28, 2024
Details:
BI 770371 is a novel antagonist anti-SIRPα monoclonal antibody (mAb) targeting both V1 and V2 SIRPα alleles makes SIRPα antagonists an option for more cancer patients.
Lead Product(s): BI 770371,Ezabenlimab
Therapeutic Area: Oncology Product Name: BI 770371
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
The funding will be used for the development of a companion diagnostic for the pivotal Phase 3 clinical trial of Tedopi (OSE2101), a neoepitope-based, off-the-shelf, cancer vaccine, in non-small cell lung cancer (NSCLC) second line treatment.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding June 20, 2023
Details:
Tedopi (OSE2101) is a neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell activation.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Tedopi (OSE2101, innovative neoepitope combination): the Company’s most advanced product; positive results for Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure.
Lead Product(s): OSE2101
Therapeutic Area: Oncology Product Name: Tedopi
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
